Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Prenetics Holding Company Limited (PRENW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PRENW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.17 | 52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -115.91% | Operating Margin (TTM) -61.41% |
Management Effectiveness
Return on Assets (TTM) -14.52% | Return on Equity (TTM) -28.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9154745 |
Shares Outstanding - | Shares Floating 9154745 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Prenetics Holding Company Limited
Company Overview
History and Background
Prenetics Holding Company Limited is a global diagnostics and genetic testing company founded in 2014. Initially focused on pharmacogenomics, it has expanded into cancer genomics, infectious disease testing, and prevention & wellness solutions. It has grown through strategic acquisitions and partnerships.
Core Business Areas
- Prevention & Wellness: Provides personalized health plans and disease risk assessment based on genetic and biomarker analysis. Products include CircleDNA.
- Cancer Genomics: Offers comprehensive genomic profiling services to guide personalized cancer treatment decisions.
- Infectious Disease Testing: Provides rapid and accurate testing solutions for various infectious diseases, including COVID-19 testing. Products include rapid antigen tests and PCR tests.
Leadership and Structure
The company is led by CEO Danny Yeung. The organizational structure includes departments focused on research and development, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- CircleDNA: A consumer DNA testing kit providing insights into health risks, diet, and ancestry. Competitors include 23andMe (owned by Alphabet (GOOGL) and AncestryDNA (owned by Blackstone (BX)). Market share data is difficult to obtain due to the fragmented nature of the consumer DNA testing market. Revenue data is not publicly available.
- Cancer Genomic Profiling Services: Comprehensive genomic profiling of tumors to identify actionable mutations and guide personalized treatment decisions. Competitors include Foundation Medicine (owned by Roche (RHHBY) and Guardant Health (GH)). Market share data is fragmented but the company reports the amount of tests that are administered yearly. Revenue data is not publicly available.
- COVID-19 Testing Solutions: Provides rapid antigen tests and PCR tests for COVID-19 detection. Market demand has decreased after 2022. Competitors include Abbott Laboratories (ABT) and QuidelOrtho Corporation (QDEL). The company has reported a decrease in revenue from this product in the last year.
Market Dynamics
Industry Overview
The diagnostics and genetic testing industry is experiencing significant growth, driven by advancements in technology, increasing healthcare expenditure, and growing awareness of personalized medicine.
Positioning
Prenetics Holding Company Limited is positioned as a provider of personalized health and disease management solutions, leveraging its expertise in genomics and diagnostics. It aims to bridge the gap between scientific advancements and consumer access to healthcare.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions of US dollars. Prenetics is positioned to capture a portion of this market through its diverse product portfolio and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Diverse Product Portfolio
- Strong Technology Platform
- Strategic Partnerships
- Global Presence
Weaknesses
- Limited Brand Recognition Compared to larger companies
- Dependence on Regulatory Approvals
- Profitability Concerns
- High Marketing Costs
Opportunities
- Expansion into New Markets
- Development of Innovative Products
- Increasing Adoption of Personalized Medicine
- Strategic Acquisitions
Threats
- Intense Competition
- Evolving Regulatory Landscape
- Data Privacy Concerns
- Economic Downturn
Competitors and Market Share
Key Competitors
- 23andMe (GOOGL)
- Guardant Health (GH)
- Exact Sciences (EXAS)
Competitive Landscape
Prenetics Holding Company Limited faces competition from larger, more established players in the diagnostics and genetic testing market. It differentiates itself through its diverse product portfolio, global presence, and focus on personalized medicine.
Major Acquisitions
DNAFit
- Year: 2018
- Acquisition Price (USD millions): 10
- Strategic Rationale: Acquisition to expand consumer health and wellness offerings.
Growth Trajectory and Initiatives
Historical Growth: Prenetics has demonstrated rapid growth in revenue and product offerings since its inception.
Future Projections: Analysts expect continued growth in revenue and profitability driven by the increasing adoption of personalized medicine and strategic initiatives.
Recent Initiatives: Recent initiatives include expanding partnerships with healthcare providers, launching new products, and entering new markets.
Summary
Prenetics shows promise due to their technology and global reach, particularly in Asia. A diverse product portfolio allows them to tap into multiple aspects of genomic testing and disease management. They face competition from more established players and need to demonstrate profitability. They must capitalize on personalized medicine trends while maintaining strong regulatory compliance and data privacy measures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Company SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available information. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Holding Company Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 285 | Website https://www.prenetics.com |
Full time employees 285 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a consumer health company, focuses on empowering individuals to take control of their health through science-backed solutions in Hong Kong, Taiwan, the United States, and internationally. The company operates in three segments: Prevention, Diagnostics, and Consumer Health. It operates IM8 Health that sells health and wellness products; and provides fulfillment and distribution services for sports nutrition products under the Consumer Health segment. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions under Prevention segment.; and ACT Genomics that provides precision oncology testing services under the Diagnostics segment. In addition, it develops and commercializes multi-cancer early detection technologies. Further, the company offers a range of genomic profiling panels tailored for requirements and clinician needs. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.